Diagnosis and management of hyperprolactinemia

Endocrinologist

Volumn 13, Issue 1, 2003, Pages 52-57

  Wand, Gary S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BROMOCRIPTINE; CABERGOLINE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; COCAINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; HALOPERIDOL; HISTAMINE H2 RECEPTOR ANTAGONIST; METHYLDOPA; OPIATE DERIVATIVE; PHENOTHIAZINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RESERPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DEPRESSION; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; FOOD AND DRUG ADMINISTRATION; GALACTORRHEA; GASTROINTESTINAL DISEASE; HEADACHE; HOT FLUSH; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOTENSION; MALE; MASTALGIA; MENSTRUATION; MICROADENOMA; MUSCLE WEAKNESS; NAUSEA; NOSE DISEASE; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; SYMPTOMATOLOGY; TUMOR VOLUME; VERTIGO; VOMITING;

EID: 0037237327     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200301000-00010     Document Type: Review

References (43)

1. Greer ME, Moraczewski T, Rakoff JS: Prevalence of hyperprolactinemia in anovulatory women. Obstet Gynecol 1980; 56: 65-9.
2. Bergh T, Nillius SJ, Wide L: Hyperprolactinaemia in amenorrhoea: Incidence and clinical significance. Acta Endocrinol (Copenh) 1977; 86: 683-94.
3. Franks S, Murray MA,Jequier AM, et al.: Incidence and significance of hyperprolactinaemia in women with amenorrhea. Clin Endocrinol (Oxf) 1975; 4: 597-607.
4. Kuku SF, Akinyanju PA, OjeifojO: Serum levels of gonadotropins, prolactin, and progesterone in infertile female Africans. Int J Fertil 1987; 32: 393-8.
5. Prathibha D, Govardhani M, Krishna PT: Prolactin levels in infertility and bromocriptine therapy in hyperprolactinaemia. J Indian Med Assoc 1994; 92: 397-9.
6. Buvat J, Lemaire A, Buvat-Herbaut M, et al.: Hyperprolactinemia and sexual function in men. Horm Res 1985; 22: 196-203.
7. Akpunonu BE, Mutgi AB, Federman DJ, et al.: Routine prolactin measurement is not necessary in the initial evaluation of male impotence. J Gen Intern Med 1994; 9: 336-8.
8. Terada T, Kovacs K, Stefaneanu L, et al.: Incidence, pathology, and recurrence of pituitary adenomas: study of 647 unselected surgical cases. Endocr Pathol 1995; 6: 301-10.
9. Faglia G: Prolactinomas and hyperprolactinemic syndrome. In Endocrinology, edited by DeGroot LJ, Jameson JL, pp. 329-42. Philadelphia, W.B. Saunders Company 2001.
10. Schlechte J, Dolan K, Sherman B, et al.: The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 1989; 68: 412-8.
11. Vanderpump MP, French JM, Appleton D, et al.: The prevalence of hyperprolactinaemia and association with markers of autoimmune thyroid disease in survivors of the Whickham Survey cohort. Clin Endocrinol (Oxf) 1998; 48: 39-44.
12. Isik AZ, Gulekli B, Zorlu CG, et al.: Endocrinological and clinical analysis of hyperprolactinemic patients with and without ultrasonically diagnosed polycystic ovarian changes. Gynecol Obstet Invest 1997; 43: 183-5.
13. Katznelson L, Klibanski A: Hyperprolactinemia: physiology and clinical approach. In Pituitary Disorders: Comprehensive Management, edited by Krisht AF, Tindall GT, pp. 189-98. Baltimore, Lippincott Williams & Wilkins 1999.
14. Von Werder K, Muller O, Fink U, et al.: Diagnosis and treatment of hyperprolactinemia. In The Pituitary Gland, edited by Imura H, pp. 453-89. New York, Raven Press, Ltd. 1994.
15. Schlechte J, el Khoury G, Kathol M, et al.: Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1987; 64: 1021-6.
16. Biller BM, Baum HB, Rosenthal DI, et al.: Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75: 692-7.
17. Nystrom E, Leman J, Lundberg PA, et al.: Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 1988; 29: 214-7.
18. Berezin M, Shimon I, Hadani M: Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 1995; 18: 436-41.
19. Carter JN, Tyson JE, Tolls G, et al.: Prolactin-secreting tumors and hypogonadism in 22 men. N Engl J Med 1978; 299: 847-52.
20. Keye WR, Jr., Chang RJ, Wilson CB, et al.: Prolactin-secreting pituitary adenomas. III. Frequency and diagnosis in amenorrheagalactorrhea. JAMA 1980; 244: 1329-32.
21. Petakov MS, Damjanovic SS, Nikolic-Durovic MM, et al.: Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21: 184-8.
22. Bevan JS, Webster J, Burke CW, et al.: Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 1992; 13: 220-40.
23. Molitch ME, Elton RL, Blackwell RE, et al.: Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 1985; 60: 698-705.
24. Webster J, Piscitelli G, Polli A, et al.: A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331: 904-9.
25. Webster J, Piscitelli G, Polli A, et al.: Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. Clin Endocrinol (Oxf) 1992; 37: 534-41.
26. Verhelst J, Abs R, Maiter D, et al.: Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999; 84: 2518-22.
27. Molitch ME, Thorner MO, Wilson C: Management of prolactinomas. J Clin Endocrinol Metab 1997; 82: 996-1000.
28. Biller BM, Molitch ME, Vance ML, et al.: Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996; 81: 2338-43.
29. Colao A, Di Sarno A, Landi ML, et al.: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 2000; 85: 2247-52.
30. Colao A, Di Sarno A, Landi ML, et al.: Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 1997; 82: 3574-9.
31. Ferrari CI, Abs R, Bevan JS, et al.: Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997; 46: 409-13.
32. Cannavo S, Curto L, Squadrito S, et al.: Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999; 22: 354-9.
33. Frankel RH, Tindall GT: Prolactinomas. In: Pituitary Disorders: Comprehensive Management. Baltimore, MD: Lippincott Williams & Wilkins; 1999: 199-207.
34. Faria MA, Jr., Tindall GT: Transsphenoidal microsurgery for prolactin-secreting pituitary adenomas. J Neurosurg 1982; 56: 33-43.
35. Domingue JN, Richmond IL, Wilson CB: Results of surgery in 114 patients with prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 1980; 137: 102-8.
36. Bertrand G, Tolis G, Montes J: Immediate and long-term results of transsphenoidal microsurgical resection of prolactinomas in 92 patients. Tolis G, Stefanis C, Mountokalakis T, eds. In: Prolactin and Prolactinomas. New York, NY: Raven Press; 1983: 441-52.
37. Serri O, Rasio E, Beauregard H, et al.: Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 1983; 309: 280-3.
38. Rodman EF, Molitch ME, Post KD, et al.: Long-term follow-up of transsphenoidal selective adenomectomy for prolactinoma. JAMA 1984; 252: 921-4.
39. Ciccarelli E, Ghigo E, Miola C, et al.: Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy. Clin Endocrinol (Oxf) 1990; 32: 583-92.
40. Feigenbaum SL, Downey DE, Wilson CB, et al.: Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. J Clin Endocrinol Metab 1996; 81: 1711-9.
41. Gemzell C, Wang CF: Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979; 31: 363-72.
42. Griffith RW, Turkalj I, Braun P: Outcome of pregnancy in mothers given bromocriptine. Br J Clin Pharmacol 1978; 5: 227-31.
43. Turkalj I, Braun P, Krupp P: Surveillance of bromocriptine in pregnancy. JAMA 1982; 247: 1589-91.